AstraZeneca: Stifel confirms its recommendation on the stock

(CercleFinance.com) - Stifel confirms its Buy rating on AstraZeneca shares, with an unchanged target price of 14,100 pence.


At the IASLC World Congress on Lung Cancer (WCLC) in San Diego, the company presented its TROPION-Lung-01 P3 trial of Dato-Dxd.

The analyst reports that the available data set raises doubts as to whether Dato-Dxd will receive direct FDA approval in the coming weeks.

An advisory committee meeting and a delayed response seem reasonable assumptions. Our interactions with the CEO on Thursday and with all management at ESMO next weekend should give us more information on the situation', concludes the broker.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.